These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 17261128

  • 1. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management.
    Quigley EM.
    J Dig Dis; 2007 Feb; 8(1):2-7. PubMed ID: 17261128
    [Abstract] [Full Text] [Related]

  • 2. Bacteria: a new player in gastrointestinal motility disorders--infections, bacterial overgrowth, and probiotics.
    Quigley EM.
    Gastroenterol Clin North Am; 2007 Sep; 36(3):735-48, xi. PubMed ID: 17950446
    [Abstract] [Full Text] [Related]

  • 3. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.
    Quigley EM, Flourie B.
    Neurogastroenterol Motil; 2007 Mar; 19(3):166-72. PubMed ID: 17300285
    [Abstract] [Full Text] [Related]

  • 4. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R.
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [Abstract] [Full Text] [Related]

  • 5. Bacterial overgrowth as a cause of irritable bowel syndrome.
    Riordan SM, Kim R.
    Curr Opin Gastroenterol; 2006 Nov; 22(6):669-73. PubMed ID: 17053447
    [Abstract] [Full Text] [Related]

  • 6. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
    Camilleri M.
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
    [Abstract] [Full Text] [Related]

  • 7. Treating irritable bowel syndrome with probiotics: the evidence.
    Parkes GC, Sanderson JD, Whelan K.
    Proc Nutr Soc; 2010 May; 69(2):187-94. PubMed ID: 20236566
    [Abstract] [Full Text] [Related]

  • 8. Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1.
    Pimentel M.
    Am J Gastroenterol; 2010 Apr; 105(4):718-21. PubMed ID: 20372119
    [Abstract] [Full Text] [Related]

  • 9. Inflammation and microflora.
    Pimentel M, Chang C.
    Gastroenterol Clin North Am; 2011 Mar; 40(1):69-85. PubMed ID: 21333901
    [Abstract] [Full Text] [Related]

  • 10. The efficacy of probiotics in IBS.
    Quigley EM.
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S85-90. PubMed ID: 18542036
    [Abstract] [Full Text] [Related]

  • 11. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment.
    Parkes GC, Brostoff J, Whelan K, Sanderson JD.
    Am J Gastroenterol; 2008 Jun; 103(6):1557-67. PubMed ID: 18513268
    [Abstract] [Full Text] [Related]

  • 12. Bacterial concepts in irritable bowel syndrome.
    Lin HC, Pimentel M.
    Rev Gastroenterol Disord; 2005 Jun; 5 Suppl 3():S3-9. PubMed ID: 17713456
    [Abstract] [Full Text] [Related]

  • 13. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets.
    Dahlqvist G, Piessevaux H.
    Acta Gastroenterol Belg; 2011 Sep; 74(3):375-80. PubMed ID: 22103040
    [Abstract] [Full Text] [Related]

  • 14. Probiotics and diverticular disease.
    Sheth A, Floch M.
    Nutr Clin Pract; 2009 Sep; 24(1):41-4. PubMed ID: 19244147
    [Abstract] [Full Text] [Related]

  • 15. [Microbiota and irritable bowel syndrome].
    Ducrotté P.
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S52-6. PubMed ID: 20889005
    [Abstract] [Full Text] [Related]

  • 16. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G, Zecchi L, Barbaro R, Cremon C, Bellacosa L, Marcellini M, De Giorgio R, Corinaldesi R, Stanghellini V.
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [Abstract] [Full Text] [Related]

  • 17. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH.
    Aliment Pharmacol Ther; 2008 Oct 15; 28(8):994-1002. PubMed ID: 18671775
    [Abstract] [Full Text] [Related]

  • 18. [Postinfectious irritable bowel syndrome].
    Döbrönte Z, Lakner L, Sarang K.
    Orv Hetil; 2006 Oct 29; 147(43):2077-80. PubMed ID: 17297754
    [Abstract] [Full Text] [Related]

  • 19. Probiotics in irritable bowel syndrome: an immunomodulatory strategy?
    Quigley EM.
    J Am Coll Nutr; 2007 Dec 29; 26(6):684S-90S. PubMed ID: 18187434
    [Abstract] [Full Text] [Related]

  • 20. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.
    Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B.
    Am J Gastroenterol; 2000 May 29; 95(5):1231-8. PubMed ID: 10811333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.